Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer is a research paper published in Vaccines (2020). On theSindex it has a DataRank of 0.637. It has been cited 24 times, with 2 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.483
From this paper's citation signal
Citation Network Contribution
0.154
From 1 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 2 citers.
National Institutes of Health
Grant: NIH SBIR R43/44 CA176920 and CA221559, NCI/NIH R01 grant CA202763 and diversity supplement CA202763-S)
NCI NIH HHS
Grant: R01 CA202763
National Institutes of Health
Grant: 5R44CA221559-02
Membrane-based vaccine with checkpoint blockade for triple negative breast cancer
National Institutes of Health
Grant: 1R43CA176920-01
A membrane-based immunotherapy for triple negative breast cancer
National Institutes of Health
Grant: 3R01CA202763-04S1
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach
FWCI
1.06
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals